首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1498597

癌症治療藥物市場規模、佔有率、成長分析、按應用、暢銷藥物、最終用戶、地區 - 產業預測，2024-2031

Cancer Therapeutics Market Size, Share, Growth Analysis, By Application, By Top Selling Drugs, By End-User, By Region - Industry Forecast 2024-2031

出版日期: 2024年06月18日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年抗癌藥物市場規模將為1366億美元，預測期內（2024-2031年）複合年成長率為9.1%，從2023年的1490.2億美元增至2031年的2991.3億美元。 10,000,000。

由於癌症發病率上升、醫療技術進步、早期診斷和治療意識增強以及易患癌症的老齡化人口增加等因素，癌症治療藥物市場正在經歷強勁成長。這一成長的關鍵是癌症治療領域的持續技術創新，包括免疫療法、標靶治療和個人化醫療，這些技術顯著改善了多種癌症類型的患者治療效果和存活率。同時，製藥業的重大研發工作導致了許多新藥的核准和擴大的治療選擇。世界各國政府和醫療保健組織也加大了對癌症研究的投資，並改善了獲得負擔得起的治療方法的機會。然而，挑戰依然存在，包括治療成本上升限制了可及性、複雜的監管障礙減緩了藥物核准，以及癌症異質性和抗藥性的持續複雜性仍然存在。克服這些障礙需要學術界、工業界和監管機構之間持續合作，以推進有效的癌症治療方法並確保更多患者受益。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 義大利
- 英國
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- 其他中東/非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

Roche Holding AG（Switzerland）
Novartis AG（Switzerland）
Merck & Co., Inc.（USA）
Pfizer Inc.（US）
AstraZeneca plc（UK）
Bristol Myers Squibb Company（USA）
AbbVie Inc.（USA）
Amgen Inc.（USA）
GlaxoSmithKline plc（United Kingdom）
Eli Lilly and Company
Takeda Pharmaceutical Company Limited（Japan）
Sanofi SA（France）
Gilead Sciences, Inc.（USA）
Bayer AG（Germany）
Johnson & Johnson USA
AbilityPharma（Spain）
Adcendo（Denmark）
Beroni Group（Australia）
BioAtla（USA）
Astellas Pharma Inc.（Japan）

簡介目錄

Product Code: SQMIG35H2214

Cancer Therapeutics Market size was valued at USD 136.6 Billion in 2022 and is poised to grow from USD 149.02 Billion in 2023 to USD 299.13 Billion by 2031, at a CAGR of 9.1% during the forecast period (2024-2031).

The cancer therapeutics market has been witnessing robust growth driven by factors such as increasing cancer prevalence, advancements in medical technology, heightened awareness of early diagnosis and treatment, and a growing ageing population vulnerable to cancer. Key to this growth is the continual innovation in cancer therapies like immunotherapies, targeted treatments, and personalized medicine, which have notably enhanced patient outcomes and survival rates across various cancer types. Concurrently, significant research and development efforts by the pharmaceutical industry have led to the approval of numerous new drugs, thereby enriching treatment options. Governments and healthcare entities worldwide have also stepped up investments in cancer research and improved access to affordable treatments. However, challenges persist, including high treatment costs limiting accessibility, complex regulatory hurdles delaying drug approvals, and the ongoing complexities of cancer heterogeneity and resistance. Overcoming these obstacles demands sustained collaborative efforts among academia, industry, and regulators to advance effective cancer therapies and ensure broader patient benefit.

Top-down and bottom-up approaches were used to estimate and validate the size of the Cancer Therapeutics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Cancer Therapeutics Market Segmental Analysis

The cancer therapeutics market is segmented based on application, top-selling drugs, end-user and region. In terms of application, the market is segmented into blood cancer, lung cancer, colorectal cancer, prostate cancer, breast cancer, cervical cancer, head and neck cancer, glioblastoma, malignant meningioma, mesothelioma, melanoma, and others. Based on top-selling drugs, the market is segmented into Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, Temodar, and others. Based on end-user, the market is segmented into hospitals, speciality clinics, and cancer and radiation therapy centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Cancer Therapeutics Market

The rising global incidence of cancer is a pivotal factor propelling the expansion of the cancer therapeutics sector. Contributing to this trend are factors like an ageing demographic, shifts in lifestyle, and increased environmental risks, all of which have led to a higher prevalence of diverse cancer types. Consequently, there is an escalating need for innovative and efficient treatment solutions, prompting extensive developments in cancer therapies and consequently boosting market growth.

Restraints in the Cancer Therapeutics Market

The primary obstacle facing the cancer treatment market is its exorbitant costs, particularly associated with advanced therapies like targeted treatments and immunotherapy. These innovative approaches often come with steep price tags, which pose significant barriers to access for patients residing in low-income areas. Moreover, the financial strain imposed by these expenses not only affects individuals but also burdens healthcare systems. Consequently, the escalating costs of cancer treatment impede the market's expansion and adoption of these cutting-edge therapies, potentially limiting their widespread availability and utilization.

Market Trends of the Cancer Therapeutics Market

The expiration of patents on numerous biologics used in cancer therapy has spurred a surge in the production and authorization of biosimilars. These biosimilars present economical alternatives to costly cancer biologics, significantly enhancing patients' ability to obtain treatment. Consequently, they have captured substantial market interest owing to their affordability, driving their widespread adoption and market expansion. Elaborating further, the expiration of patents for various cancer biologics has led to an uptick in the production of biosimilars, which are cheaper alternatives. This shift has democratized access to cancer treatment, benefiting a larger number of patients who previously faced financial barriers. Biosimilars' cost-effectiveness has not only attracted significant attention from healthcare providers but has also spurred growth in the market. As a result, biosimilars are increasingly becoming a preferred choice, not only due to their affordability but also for their role in broadening access to critical therapies across diverse patient populations.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Pricing Analysis
Ecosystem of the Market
Start-up Analysis
Regulatory Landscape
Innovation Matrix
Value Chain Analysis
Pipeline Analysis
Patent Analysis
Top Investment Analysis
Key Success Factor
Market Attractive Index
Degree of Competition

Cancer Therapeutics Market by Cancer Type

Market Overview
Blood Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Breast Cancer
Cervical Cancer
Head and Neck Cancer
Glioblastoma
Malignant Meningioma
Mesothelioma
Melanoma
Others

Cancer Therapeutics Market by Therapy Type

Market Overview
Chemotherapy
Targeted Therapy
Immunotherapy
Hormonal Therapy
Other Treatment Types

Cancer Therapeutics Market by Top Selling Drugs

Market Overview
Revlimid
Avastin
Herceptin
Rituxan
Opdivo
Gleevec
Velcade
Imbruvica
Ibrance
Zytiga
Alimta
Xtandi
Tarceva
Perjeta
Temodar
Others

Cancer Therapeutics Market by End User

Market Overview
Hospitals
Specialty Clinics
Cancer and Radiation Therapy Centers

Cancer Therapeutics Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- Italy
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson USA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbilityPharma (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adcendo (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Beroni Group (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioAtla (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments